Objective: To perform comprehensive network and pathway analyses of the genes known to cause genetic hearing loss. Study Design: In silico analysis of deafness genes using ingenuity pathway analysis (IPA). Methods: Genes relevant for hearing and deafness were identified through PubMed literature searches and the Hereditary Hearing Loss Homepage. The genes were assembled into 3 groups: 63 genes that cause nonsyndromic deafness, 107 genes that cause nonsyndromic or syndromic sensorineural deafness, and 112 genes associated with otic capsule development and malformations. Each group of genes was analyzed using IPA to discover the most interconnected, that is, ''nodal'' molecules, within the most statistically significant networks (p G 10 j45
).
Results: The number of networks that met our criterion for significance was 1 for Group 1 and 2 for Groups 2 and 3. Nodal molecules of these networks were as follows: transforming growth factor beta1 (TGFB1) for Group 1, MAPK3/MAPK1 MAP kinase (ERK 1/2) and the G protein coupled receptors (GPCR) for Group 2, and TGFB1 and hepatocyte nuclear factor 4 alpha (HNF4A) for Group 3. The nodal molecules included not only those known to be associated with deafness (GPCR), or with predisposition to otosclerosis (TGFB1), but also novel genes that have not been described in the cochlea (HNF4A) and signaling kinases (ERK 1/2). Conclusion: A number of molecules that are likely to be key mediators of genetic hearing loss were identified through three different network and pathway analyses. The molecules included new candidate genes for deafness. Therapies targeting these molecules may be useful to treat deafness. Key Words: Deafness genesVERK 1/2VGPCRVHNF4AVMAPK1VMolecular pathways analysisV TGFB1.
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Hearing loss is the most common sensory deficit in the world, affecting almost 600 million people (1) , and the most common congenital anomaly, affecting 2 to 6 per 1,000 newborns (1, 2) . At least two-thirds of cases of prelingual deafness in the developed countries are due to genetic factors; the remaining one-third is attributed to environmental and unidentified genetic factors (3) .
In general, genetic hearing loss can be classified as syndromic or nonsyndromic, depending on whether other distinguishing physical features are present or absent, respectively. Nonsyndromic hearing loss is typically sensorineural and believed to account for 70% of cases (4) . The remaining 30% of hearing loss is syndromic and can be sensorineural, conductive, or mixed. More than 400 syndromes include hearing loss as a part of their phenotypic signature (3) . Typically, genetic hearing loss is monogenic. Based on the mode of inheritance, monogenic hearing loss is classified as autosomal recessive, accounting for 80% of cases; autosomal dominant, accounting for almost 20% of cases; X-linked; and mitochondrial; the latter two account for less than 1% of cases (5) .
Hearing loss is one of the most genetically heterogeneous disorders, with more than 100 mapped loci and more than 60 causally implicated genes within these loci (6) . Additional complexity exists because mutations in the same gene may cause syndromic or nonsyndromic hearing loss, and hearing loss may be oligogenic (7) . Given the intricacy of normal hearing, which requires interaction of many diverse molecules, it is estimated that approximately 1% of human genes play a role in hearing (8) .
Although the shear number of genes involved in hearing and deafness may seem daunting, this complexity may be simplified by looking at well-characterized cell signaling and metabolic pathways through which these genes are known to interact in various tissues. A common assumption of pathway analysis is that genes whose dysfunction contributes to a disease phenotype tend to be functionally related (9, 10) . Unraveling these pathways is essential to understanding biological mechanisms, disease states, and the function of drugs that affect them. We therefore undertook the first comprehensive pathway and network analysis of all known genes implicated in human deafness. We used tools of bioinformatics to analyze interactions across multiple biological dimensions including molecular interactions, cellular processes, and disease processes. We focused on 3 groups of genes: those causing nonsyndromic hearing loss, those causing nonsyndromic or syndromic sensorineural hearing loss, and those associated with malformation of the otic capsule. The third group of genes was augmented with genes implicated in otic capsule development based on animal studies in mammals. Our analyses suggest new candidate genes for deafness within the known deafness loci and highlight several genes as potential novel targets for diagnosis and treatment of genetic hearing loss.
MATERIALS AND METHODS
A PubMed English search was performed to identify genes and molecules associated with human hearing loss and with mammalian development and malformation of the otic capsule. All genes listed on the Hereditary Hearing Loss Homepage entered our analyses. The pertinent genes were identified through linkage analysis, immunohistochemistry, quantitative reverse transcription-polymerase chain reaction, or microarray analyses. Only studies with relevant controls or appropriate statistical analyses were included; studies without control groups or with unspecified statistical significance were excluded. Genes that met our criteria were classified based on their established role in nonsyndromic or syndromic sensorineural hearing loss, or association with otic capsule development or malformation. The number of genes that entered our analyses was 63 genes that cause nonsyndromic deafness, 107 genes that cause nonsyndromic or syndromic sensorineural deafness, and 112 genes associated with otic capsule development and malformations (Table S1 , Supplemental Digital Content 1, http://links.lww.com/MAO/A149, alphabetically lists genes used in the analyses, along with their associated clinical phenotypes). The second analysis was done to enrich for genes associated with sensorineural hearing loss, whereas the third analysis was done to enrich for genes that contribute to mixed conductive and sensorineural hearing loss.
For each of the 3 groups of genes, a different analysis was performed using ingenuity pathway analysis software (IPA; Ingenuity Systems, Redwood City, CA, USA), which is based on the world's largest curated and highest quality knowledge base of biological networks created from millions of individually modeled relationships among proteins, genes, complexes, cells, tissues, drugs, and diseases to understand how candidate genes may work together as molecular modules that impact cellular processes and disease phenotypes. Within IPA, pathway refers to well-characterized cell signaling and metabolic pathways based on molecular and biochemical studies, whereas network refers to regulatory relationships that exist among userspecified molecules. We refer to the most interconnected molecule (or class of molecules) in a network as key or central node. Networks of up to 140 molecules were studied to allow for the possibility that all genes within a group belonged to the same network. Statistical analysis of networks and pathways was performed as part of the overall IPA using the right-tailed Fisher's exact test (11) . The p value reflects the likelihood that the association between the input genes and a given pathway or network is due to chance. Only networks with p G 10 j45 were considered significant. Less stringent criterion of p G 0.05 was used for pathway significance to facilitate discovery of potentially novel signaling pathways.
Expression of select genes was validated by summarizing their reported expression in the mouse cochlear hair cells based on RNASeq (12) or mouse spiral ganglion neurons based on GeneChips (13) . Both databases catalog changes in gene expression during embryonic and early postnatal development.
RESULTS
Network analysis of the nonsyndromic deafness genes revealed 6 networks. The top network was very highly significant (p = 10 j105 ) and included nearly all (50 of 63) genes currently implicated in nonsyndromic HL, suggesting close coupling of deafness genes within the cacophony of human interactome. This network is shown in Figure S1 , Supplemental Digital Content 2, http://links.lww.com/MAO/A150, and all molecules of the network are listed in Table S2 , Supplemental Digital Content 7, http://links.lww.com/MAO/A155. The remaining 5 networks did not meet our criterion for significance (p = 10 j2 ). The central node of the top pathway was transforming growth factor beta1 (TGFB1), having 35 connections with other genes in the network (Fig. 1) . The second and third central nodes were beta-estradiol and filamentous actin (F-Actin), with 29 and 24 gene interconnections, respectively (Table 1 ). Pathway analysis revealed 5 statistically significant pathways (Table 2) , highlighting the importance of actin cytoskeleton signaling, which is known to be critical for stereociliar and hair cell function. The second ranked pathway was cell junction signaling (Table 2) , consistent with the observations that about 50% of cases of nonsyndromic HL are due to mutations in GJB2 encoding a gap junction protein (14) . The other top pathways point to previously understudied pathways in the context of deafness, that is, hepatic fibrosis, and signaling via sildenafil (Viagra) or integrin-linked kinase (Table 2) .
Network analysis of genes causing both nonsyndromic and syndromic sensorineural deafness generated 10 networks, two of which met our criterion for statistical significance (with p = 10 j103 and p = 10 j46 ); the other networks had p e 10 j2 . The central node of the top network was MAPK3/MAPK1 MAP kinase (ERK 1/2) with 33 connections, closely followed by collagens with 32 connections, and hepatocyte growth factor (HGF) with 30 connections (Table 1 Table S4 , Supplemental Digital Content 9, http://links.lww.com/MAO/A157, listing all molecules of this network). This node was more than 3 times more interconnected than the second and third key nodesVbeta estradiol with 24 connections and TGFB1 with 21 connections. Pathway analysis pointed to the potential relevance of signaling pathways in melanocytes, melanoma, and renal cell carcinoma for sensorineural deafness (Table 2) , in addition to the pathways already highlighted in the first analysis.
Network analysis of genes involved in otic capsule development and malformation syndromes generated 4 networks, 2 of which met our criterion for statistical significance (with p = 10 j105 and p = 10 (44) TNF (31) HL indicates hearing loss.
for deafness and cochlear malformation, including signaling pathways in rheumatoid arthritis, cardiogenesis, stem cells pluripotency, chromosomal replication, and BMP signaling (Table 2) . Chromosomal locations of the top nodes listed in Table 1 are provided in Table 3 , along with the corresponding human and mouse deafness loci, and the reported expression in the mouse cochlea. Similar information is provided for all genes in Supplemental Tables S2YS6. Of the 10 nodal molecules in Table 3 , six represent novel candidate genes for human deafness because of their location within human deafness loci with unknown causative genes (MAPK1, HNF4A, BMP4, TNF) or within human deafness loci where another gene has been identified as causative (TGFB1, CYP19A1), and their documented expression in the mouse cochlea. When analyzing all genes comprehensively across the studied networks (Supplemental Tables S2-S6), many represent additional candidate genes for human deafness because of their chromosomal location within deafness loci with unknown causative genes or within deafness loci where known causative genes are different than the candidate genes. Focusing on the former, we have selected 25 genes whose expression has been unambiguously documented in murine cochlear hair cells (12) or cochlear neurons (13) ( Table 4 ). In addition, the genes that are known to cause syndromic hearing loss in humans are attractive candidates for human nonsyndromic hearing loss when they fall within the loci for nonsyndromic deafness (Supplemental Tables S1YS6) because several well-studied genes, such as MYO7A (15,16) and SLC26A4 (17, 18) , are known to cause syndromic or nonsyndromic hearing loss, depending on the location and severity of a mutation.
DISCUSSION
A comprehensive network and pathway analysis of the human deafness genes has revealed that these genes form a small and well-interconnected neighborhood in the cacophony of the human interactome, as reflected in the very highly significant top networks for each of the 3 analyses that we performed. Using musical analogy, a node is a note or a chord, a pathway is an instrumental tune linking interconnected notes and chords, and a network is a symphony involving interconnected tunes from many different instruments. In this harmony of sound, TGFB1 stands out as the only note of central significance in all 3 analyses (Table 1) . Although mutations in this gene are known to cause Camurati-Engelmann disease (19) and a coding polymorphism in TGFB1 is associated with otosclerosis (20), TGFB1 has not been causally linked to nonsyndromic sensorineural hearing loss; our results strongly support future exploration of this potential causal link. TGFB1 is a multifunctional peptide that controls proliferation, differentiation, extracellular matrix production, adhesion, migration, and other functions in many cell types (21) . In the inner ear, TGFB1 stimulates otic capsule chondrogenesis during early development (22) and controls remodeling of the developing otic capsule by inhibiting osteoclast activation and stimulating osteoblast differentiation (23) . Our results suggest that TGFB1 may play additional, as of yet unrecognized, roles in the physiology of the cochlear sensorineural structures, in addition to its established role in otic capsule development and remodeling. Interestingly, BMP4, which we have identified as another candidate gene for human deafness (Table 1) , is a member of the TGFB superfamily of signaling molecules (24) .
Beta-estradiol is another prominent node in the analyses of nonsyndromic and syndromic sensorineural hearing loss (Table 1) . This molecule is a sex hormone derived from cholesterol, present not only in women but also in men because it is derived from testosterone by the action of aromatase. In addition to its critical role in reproduction and sexual function, beta estradiol has an osteoprotective (25), neuroprotective (26) , and otoprotective role (27) . It is interesting that the gene encoding aromatase, called CYP19A1, is located on chromosome 15q21.1, which falls within the DFNB16 deafness locus (Table 3 ). This strongly motivates future studies of the role CYP19A1 plays in hearing and deafness.
Another key node is ERK1/2 (Table 1) Va chord with 2 notes: ERK1 and ERK2. ERK1/2 are signaling kinases that are members of the mitogen-activated protein kinases (MAPKs) with contrasting function, depending on stimulus: ERK1/2 activation promotes cell proliferation and survival (28, 29) , or cell death and apoptosis (30) . Although MAPKs can be activated by a broad variety of stimuli, it is interesting that ERK 1/2 are frequently activated by GPCR (31)Vanother key node in the analysis of syndromic and nonsyndromic sensorineural deafness (Table 1) . Although mutations in genes encoding ERK1 and ERK2, called MAPK3 and MAPK1, respectively, have not been implicated in human deafness, MAPK1 is located within the DFNB40 locus (Table 3 ). Our results motivate future studies of MAPK1 as a possible causative gene for DFNB40 nonsyndromic, autosomal recessive, profound, prelingual deafness. Our results also motivate future studies of ERK1/2 signaling in otic capsule development and function (Table 1) .
Animal models point to ERK1/2 being important for hearing. Inhibition of ERK 1/2 activation causes loss of outer hair cells and enhancement of gentamicin ototoxicity in cochlear explants (32) . In contrast, ERK 1/2 activation frequently signals damage in the neonatal rat cochlea, and neomycin-induced ERK 1/2 activation in supporting cells promotes hair cell death (33) .
G protein coupled receptors represent the central node of the second most significant network in the analysis of nonsyndromic and syndromic sensorineural deafness (Table 1) . GPCR are a large family of proteins, including approximately 800 different members divided into 5 subfamilies, all located within the plasma membrane. They are activated by many different ligands, conveying the vast majority of signal transduction across cell membranes, and regulating diverse physiologic processes (34, 35) . GPCR family has been associated with deafness, as mutations of its largest member, VLGRI, are responsible for Usher syndrome, type 2C (36) . Many GPCR genes are novel candidates for deafness genes (Table 4 and Supplemental Table S4 ).
When analyzing genes involved in otic capsule development and malformation, the central node of the second most significant network was HNF4A whose role in hearing has not been previously studied. HNF4A is a transcription factor mainly expressed in the liver but also in the small intestine, colon, kidney, and pancreatic beta cells (37, 38) . HNF4A is critically involved in the regulation of the expression of many hepatic genes; its absence causes metabolic dysfunction and death (39Y41). In addition, HFN4A regulates the expression of genes encoding coagulation factors XII and XIIIb (42) . Heterozygous mutations in HNF4A are associated with maturity-onset diabetes of the young, Type 1 (MODY-1), characterized by abnormal secretion of insulin by the B cell of pancreas after glucose stimulation, with normal liver function and insulin sensitivity (43) . Hearing has not been studied in people with MODY-1. Chromosomal location of HNF4A on 20q13.12 within the DFNB65 locus makes HNF4A an attractive candidate gene for human deafness (Table 3) . Entries with ''+'' indicate families of proteins. Genes highlighted in bold represent novel candidates for deafness genes because they are located within deafness loci that await identification of causative genes (**) or within deafness loci where another gene has been identified as causative (-). Beta estradiol is marked with ''^'' because it is a steroid, not encoded by a gene. However, its conversion from testosterone is mediated by the highlighted gene CYP19A1.^: Among the listed molecules, only Hgf is known to cause deafness in the mouse (nonsyndromic) (75) . Expression refers to mouse cochlear hair cells (H) 12 or cochlear neurons (N) 13 . TABLE 4. Additional candidate genes for human deafness based on their presence in the networks studied (Table 1, and Supplemental Tables S2Y26), unreported association with human deafness (Supplemental Table S1 ), and chromosomal location within deafness loci whose causative genes remain unidentified (**)
IPA symbol
Entrez gene name (74) Entrez gene ID for human (74) Location in human (74) Deafness locus in human (6) Entrez gene ID for mouse (74) 12 or cochlear neurons (N) 13 .
Emergence of the proinflammatory cytokine, TNF, as a candidate gene for deafness is intriguing because diverse inflammatory conditions, such as otitis media and autoimmune disease, can cause hearing loss (44) , whereas anti-inflammatory medications, such as steroids (45, 46) and TNF blockers (44) , can ameliorate hearing loss. However, chronic use of some nonsteroidal anti-inflammatory medications has been associated with hearing loss, in a sexdependent manner (47, 48) , highlighting the importance of understanding genetic underpinning of cochlear response to inflammation.
By exploring topologic characteristics of deafness genes in the human interactome, we have also discovered biologic processes that provide a global prospective on deafness ( Table 2 ). Some of these processes provide surprising new insight into mechanisms that may be shared between the process of hearing and diverse processes such as melanoma signaling, cardiogenesis, and hepatic fibrosis. Our finding that the canonical pathway for cellular effects of sildenafil (Viagra) is relevant for sensorineural hearing loss is consistent with the reported sudden hearing loss from phosphodiesterase-5 inhibitors used to treat erectile dysfunction (49) .
In addition to identifying molecules and pathways of key relevance for hearing and hearing loss, our analyses have predicted drug targets to treat or prevent hearing loss. Although emerging therapies for deafness are likely to benefit from rapid developments of pharmacotherapies in seemingly unrelated fields, such as cancer biology or sexual dysfunction, we need to be cognizant of potentially harmful effects of these therapies on hearing. Many different drugs are known to target the top nodal molecules of the 5 networks that we analyzed ( Table 1) .
Majority of the existing drugs that target TGFB1 focus on enhancing TGFB1 activation to promote chondrogenesis or new bone formation. However, several studies propose inhibition of gene function using agents such as neutralizing antibodies, soluble receptors, receptor kinase antagonists, antisense reagents, and specific drugs (50) . The commonly used drugs that are capable of blocking TGFB1, among their other functions, include antagonists of angiotensin II, Type 1 receptors (e.g., losartan), angiotensin-converting enzyme (ACE) inhibitors (51Y56), statins (especially simvastatin) (57Y60), the oral antimicrobial pirfenidone (61,62) (InterMune Inc., CA, USA), and the antifibrotic drug tranilast (63) (Kissei Pharma, Japan). Furthermore, a number of specific TGFB1 inhibitors are being investigated, including the pan-TGF-b monoclonal antibody (64), the soluble TGF-ARII receptor, antisense oligonucleotides, and inhibitors of ALK5 (50) . Interestingly, long-term treatment with the anti-TGF-b mAb was not found to result in significant pathologic changes in major organs and tissues in mice (64) , although other studies have raised concerns regarding the potential acceleration of tumor progression after TGF-b inhibition (65) .
Regarding GPCR, which are involved in nearly all human physiologic processes, about half of the currently available drugs on the market nonspecifically target members of this superfamily (34) . Therefore, specific targeting of GPCR most relevant for hearing may be challenging.
Blockage of the ERK1/2 pathway has been of great interest for cancer biology because of the pathway's known role in cancer aggressiveness. Although powerful inhibitors of ERK 1/2 pathway have been described with promising results (66, 67) , the production of specific drugs targeting these signaling kinases remains challenging. Given the reported dual role of ERK1/2 in cochlear physiology and pathophysiology, any therapeutic manipulation of the ERK1/2 pathway will have to be leveraged against the risk of worsening or accelerating hearing loss with such manipulation.
Interestingly, HNF4A expression is inhibited by cyclosporine (68), a commonly used drug whose chronic use is associated with hearing loss (69) . This further highlights a likely important role of HNF4A in hearing. Other substances reported to inhibit HNF4A gene expression and function include the tumor suppressor P53 (70), cytokines, and the peroxisome-proliferatorYactivated receptor-F coactivator 1> (71) . Curiously, fasting upregulates and feeding downregulates HNF4A expression (72) , suggesting future dietary measures to modulate the levels and activity of HNF4A (73) .
CONCLUSION
This study is the first systematic network and pathway analysis of human deafness genes. By studying genetic chords, tunes, and symphonies we have identified novel candidate genes for deafness and highlighted biologic processes that may provide better understanding of hearing and hearing loss. Our analyses have implications for design of new drugs and therapies to prevent or treat deafness and for strategies to benefit from parallel developments of pharmacotherapies in other fields of medicine. A caveat of the study is that it is based on the knowledge databases that are always evolving because of new discoveries that are integrated into the databases. Therefore, our analyses inevitably represent a snapshot in time.
